Physician profile

Matthew Ryan Haack

Pulmonary Disease · Canton, GA

NPI 1811186828

$3,788.95

in general payments reported to CMS, 2019-2025

34 companies · $1,034 in 2025

The $1,034 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,958.22
Education$122.47

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $725.53 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Electromed, INC. $527.13 2019-2025 Smartvest
Grifols USA, LLC $388.79 2019-2024 Prolastin-C Liquid
Astrazeneca Pharmaceuticals LP $278.20 2019-2025 Airsupra, Breztri, Tezspire
Genzyme Corporation $224.90 2021-2025
Actelion Pharmaceuticals US, INC. $204.04 2024-2025 Opsumit, Uptravi
Intuitive Surgical, INC. $173.29 2022
Jazz Pharmaceuticals INC. $148.58 2024-2025
Boehringer Ingelheim Pharmaceuticals, INC. $134.41 2019-2025 Ofev
Philips North America LLC $120.41 2019-2022
Mylan Specialty L.P. $95.97 2019-2022
Sunovion Pharmaceuticals INC. $78.11 2019
Baxter Healthcare $63.17 2022-2025 Hillrom - Vest System Model 105 Home Care
Viatris Specialty LLC $58.56 2025 Yupelri
Sanofi-Aventis U.S. LLC $57.48 2023
Show all 34 companies
CompanyGeneral paymentsYearsTop products
Takeda Pharmaceuticals U.S.A., INC. $52.70 2025 Glassia
Regeneron Healthcare Solutions, INC. $43.97 2024-2025 Dupixent
Insmed, INC. $43.21 2022-2024 Arikayce
Pfizer INC. $41.54 2022-2025
Verona Pharma, INC. $36.52 2025 Ohtuvayre
Merck Sharp & Dohme LLC $34.98 2024 Winrevair
Amgen INC. $33.49 2025 Tezspire
United Therapeutics Corporation $25.74 2021-2023 Tyvaso
Tactile Systems Technology INC $24.62 2024 Entre Plus, Flexitouch Plus
Axsome Therapeutics, INC. $23.41 2025 Sunosi
Advanced Respiratory, INC $22.07 2019
Idorsia Pharmaceuticals US INC $20.83 2023 Quviviq
Lilly USA, LLC $16.92 2025 Zepbound
Janssen Pharmaceuticals, INC $16.81 2020
Genentech USA, INC. $16.11 2019
Resmed Corp $15.38 2024
Galvanize Therapeutics, INC $15.15 2024 Aliya System
Gilead Sciences, INC. $13.85 2021
Pulmonx Corporation $13.08 2024 Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Matthew Ryan Haack

$3,788.95

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $1,034 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/355019/matthew-ryan-haack

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.